Mobile Menu - OpenMobile Menu - Closed

VIDEO: Rep. Kind Pushes to Allow Medicare to Negotiate Prescription Drug Prices

October 17, 2019
Press Release

Washington, DC—Today, during a Ways and Means Committee hearing about lowering the cost of prescription drugs, Rep. Ron Kind urged his colleagues to support legislation that would allow Medicare to negotiate prescription drug prices—a main pillar of the Congressman’s Drug Pricing Action Plan.

Watch the video here


  • Rep. Kind: “Drug companies are the only private companies that do business with the federal government where we are specifically prohibited to talk price with them.”


  • Rep. Kind: “And I'll tell you who [HR 3] doesn't divide, it doesn't divide the American people. Because when I bring this up back home all of them are shaking their heads--and they may not be Nobel prize-winning economist--but they know when the gig is up and that something isn't on the level here. And they think it's ridiculous that we have a prohibition on price negotiation with the pharmaceutical industry.”


  • Rep. Kind: “And then…the Chairman of the [Energy and] Commerce Committee who was instrumental in getting the non-negotiating language…suddenly left Congress and became the head lobbyist for the pharmaceutical industry here in Washington.”


  • Rep. Kind: “And I'll tell you who else [HR 3] doesn't divide, the President of the United States who campaigned on HR 3--he may not have known what the name was at the time, but back in 2016 he said he wanted to restore price negotiation for these drugs. And that's exactly what we're doing now.”


Last week, Rep. Kind introduced the Better Transparency in Information for Medicare Beneficiaries Act of 2019. This legislation will increase transparency by providing notice to seniors when less expensive Medicare prescription drug plans are available to them.

This summer, Rep. Kind unveiled his Drug Pricing Action Plan made up of bipartisan solutions aimed at lowering costs for Wisconsinites by:

  • Lowering out-of-pocket costs for patients
  • Allowing Medicare to negotiate drug prices
  • Promoting price transparency & accountability
  • Stopping patent abuse